Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.39 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10631607 | 0.86 | RAB9A (0.44) | MEN1MAPTKMT2ANPC1PABPC1 | |
| SCHEMBL15942899 | 0.82 | GAA (0.49) | MEN1MAPTKMT2ANPC1PABPC1 | |
| SCHEMBL4386497 | 0.78 | NOS2 (0.47) | MAPTNPC1RAB9ALCK | |
| SCHEMBL28406968 | 0.77 | CDK8 (0.35) | MEN1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL18146934 | 0.73 | FBP1 (0.46) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL3331353 | 0.72 | MAPT (0.50) | MEN1MAPTKMT2ANPC1PABPC1 | |
| SCHEMBL1553839 | 0.71 | F11 (0.46) | ADORA3 | |
| SCHEMBL1553840 | 0.71 | F11 (0.46) | ADORA3 | |
| SCHEMBL1886893 | 0.71 | NPC1 (0.62) | MEN1MAPTKMT2ANPC1PABPC1 | |
| SCHEMBL11341693 | 0.71 | HRH4 (0.53) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957057-A1 | STRUCTURAL CAROTENOID ANALOGS OR DERIVATIVES FOR THE MODULATION OF SYSTEMIC AND/OR TARGET ORGAN REDOX STATUS | Cardax Pharmaceuticals, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070238793-A1 | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status | CARDAX PHARMACEUTICALS, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007067957-A1 | STRUCTURAL CAROTENOID ANALOGS OR DERIVATIVES FOR THE MODULATION OF SYSTEMIC AND/OR TARGET ORGAN REDOX STATUS | CARDAX PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070087360-A1 | Methods and compositions for detecting nucleotides | APPLIED BIOSYSTEMS, LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070020667-A1 | Methods and compositions for amplifying nucleic acids | APPLIED BIOSYSTEMS, LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006028496-A2 | LESION REPAIR POLYMERASE COMPOSITIONS | APPLERA CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050215529-A1 | Method of treating oxidative stress-associated conditions with isopentenyl diphosphate | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-09-29 | — | — | US | disclosed |
| US-20050196392-A1 | Primer extension reactions, DNA sequencing, genotyping, and nucleic acid amplification techniques such as the polymerase chain reaction; kit comprising a terminator, a buffering agent, a divalent cation, and an additive | APPLIED BIOSYSTEMS, LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020667-A1 | Methods and compositions for amplifying nucleic acids | POLRMT, POLN, RNGTT | MEN1 853/4885MAPT 3000/4885KMT2A 1503/4885 |
| US-20050196392-A1 | Primer extension reactions, DNA sequencing, genotyping, and nucleic acid amplification techniques such as the polymerase chain reaction; kit comprising a terminator, a buffering agent, a divalent cation, and an additive | POLB, POLH, POLN | MEN1 1407/4885MAPT 4341/4885KMT2A 1961/4885 |
| US-20070238793-A1 | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status | LPO, TXN2, TXNRD2 | MEN1 3729/4885MAPT 3121/4885KMT2A 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.